A Study Comparing the Efficacy and Safety of the Morning Injection of Toujeo Versus Lantus in Patients With Type 1 Diabetes Mellitus

  • sponsor
Updated on 25 March 2021


A Study Comparing the Efficacy and Safety of the Morning Injection of Toujeo Versus Lantus in Patients With Type 1 Diabetes Mellitus


Primary objective:
To demonstrate that morning injection of Toujeo compared to Lantus will provide better glycemic control evaluated by Continuous Glucose Monitoring (CGM) in adult patients with type 1 diabetes mellitus.

Secondary objective(s):
To demonstrate that treatment with Toujeo compared to Lantus will provide

  • lower incidence rate of nocturnal symptomatic hypoglycemia,
  • better glucose control coverage during the last hours of CGM before next basal-insulin dosing;
  • less variability in CGM profile.

Condition Diabetes Mellitus, Type 1
Clinical Study IdentifierTX144418
Last Modified on25 March 2021


Yes No Not Sure

Inclusion Criteria

Adult patients (male and female) with type 1 diabetes mellitus
Signed written informed consent

Exclusion Criteria

Age <18 years or >70 years
Fasting c-peptide ≥0.3nmol/l as per source document or central lab test at Visit 1
HbA1c <7.0% or >9.0% via central lab test at Visit 1
Patients who experienced none or only 1 episode of documented symptomatic and/or severe hypoglycemia (as per the ADA classification) during the past month prior to screening
Patients who experienced >1 episode of severe hypoglycemia resulting in coma/seizures during the last 12 months before screening
Patients receiving less than 1 year treatment with basal plus mealtime insulin
Using any basal insulins other than Lantus in the past 3 months before screening
Requiring >80 U/day Lantus and/or not on stable Lantus dose (± 20% total dose) within 30 days prior to screening
Using fewer than 2 injections of rapid-acting insulin analog per day within 30 days prior to screening
Using human regular insulin as mealtime insulin within 30 days prior to screening
Using an insulin pump during the last 6 months before screening
History of unstable proliferative diabetic retinopathy or any other rapidly progressive diabetic retinopathy or macular edema likely to require treatment (eg, laser, surgical treatment or injectable drugs) during the study period
Pregnant or breast-feeding women or planning pregnancy during the duration of the study
Use of any other investigational drug(s) within 1 month or 5 halflives, whichever is longer prior to screening
Inappropriate CGM use during screening period evidenced by failure to obtain a minimum of 4 days of usable records by the end of screening
Non-compliance with SMPG performance evidenced by failure to demonstrate at least 5 days of 5-point SMPG records by the end of screening
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer  to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact


Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note